Scancell Share Discussion Threads

[nigelpm] 05/4/2024 22:18

Bizarrely though with all the great news that has come before somehow we are languishing at 10p - risk:reward really does favour the brave here.

[nigelpm] 05/4/2024 22:15

Still too premature to be getting excited and slapping backs. The 25 week data as you note is crucial.

[inanaco] 05/4/2024 22:09

well that bit is new

Results 19 patients received the combination of SCIB1 with nivolumab and ipilimumab. At study entry, all patients were stage IV.

the other data was given out only 8 weeks ago

really we want the 25 week data on 43 patients ...

but .... each release of news gives us the 90% probability because they are still responding and no patient is going backwards

we are buying for the results ... at 10.5p with a 90% probability

now over 1.5m

[nigelpm] 05/4/2024 22:03

We knew that on the 17th January no?

[inanaco] 05/4/2024 21:09

from LSE

glad i topped up .....

all looking good then big win coming and the best part the patients that have been on the trial longest are not showing any signs of new lesions

Results 19 patients received the combination of SCIB1 with nivolumab and ipilimumab. At study entry, all patients were stage IV. 13 patients had reached the first imaging timepoint at 13 weeks, and the objective response rate is 85%. 9/9 responses were confirmed in a subsequent scan. Patients showed a 40-95% reduction in tumor volume between 13 and 25 weeks. Most of the SCIB1-related adverse events were Grade 1/2. Only 1 patient reported a Grade 3 rash. No enhancement of immune-mediated adverse events was observed when SCIB1 was added to nivolumab with ipilimumab.

Conclusions SCIB1 in combination with nivolumab and ipilimumab as first line treatment for unresectable melanoma improved the ORR to 85% without an increase in clinically meaningful adverse events. These results if confirmed in a larger patient cohort provide confidence in initiating a randomized registration program in unresectable melanoma patients with the novel DNA plasmid technology

[marcusl2] 04/4/2024 16:34

In the News: We asked the CEO of @SutroBio, an ADC developer whose lead program targets folate receptor alpha, what his reaction was to yesterday’s acquisition of ProfoundBio.




Dr David Pinato, Principal Investigator at Imperial College, commented: “Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in patients who have exhausted most treatment options is very encouraging”.

High-grade serous ovarian cancer (HGSOC) is the most common type of ovarian cancer, accounting for 75% of epithelial ovarian cancers. It is an aggressive disease which is typically diagnosed at a late stage and develops drug resistance. New therapeutic strategies are therefore required to treat this disease.

[marcusl2] 04/4/2024 16:04

The agency is still separately working on the specifics of the “platform” designation. The idea would be that products developed with the same platform technologies may enjoy streamlined reviews for subsequent advances.

The FDA has had the “platform” idea for some time. But it hasn’t really applied the idea to the fullest extent possible, Marks said.

“I think the mRNA platforms are going to force us to really try to lean into that," Marks added.

[marcusl2] 04/4/2024 15:58

Merck KGaA signs $1.4B biobuck deal with Caris to expand ADC pipeline

[torquayfan] 04/4/2024 14:36

Octopus. Conclusions unrelated. Just more than one Employee exercising some options. Big deal. Just a tiny no.of new shares admitted. Relax.

[markingtime] 04/4/2024 11:49

Nonsense. You are suggesting that the option exercise is both still employed and exercises some managerial control. At least one of those is unlikely to be true, as one can infer from the pocket money number of share options being exercised.

[octopus100] 04/4/2024 10:20

My thoughts on next update would be possibly at the AACR next week - however stacking against that is the fact that employees exercised share options and if thats the case that would imply they are in an open period so that there is no news to be released that hasn't been already or they wouldnt have been able to exercise options.
Guess on the plus side they wouldn't have exercised unless they thought things were going well.

[bermudashorts] 04/4/2024 10:15

Why present a late breaking abstract if there's no updated data?

[inanaco] 04/4/2024 09:16

does not matter what people think about timing ..........

the trials are in control over the release of Data and how Scancell present it ....

from Scancells perspective the industry is more important as the BOD manage the company on shareholders behalf, The Stock market is a trade of the shares its not a place to sell our products thus presenting the data to the industry takes priority, with an RNS to follow

however because its so cheap ............ its a case of Buy Buy Buy this week i have added another £2400 taking my years spend to £44k ISA plus trading account

why do that ?

scib1 carries a predicted 90% success rate ............ with sales at approval of £1.5b on a brand new patent if ISCIB1 works as intended

this high efficacy rates are astonishing in an industry that chases "months" in improvements as highly valuable

efficacy and safety makes for an easy approval .............

the competition have just reported UV1 ..... it failed

which means more attention on Scancell and how did they make it work ?

immunobody and its ability to generate those High Avidity T cells

look at my history SCIB1 no risk

ATB

[nigelpm] 04/4/2024 08:07

What's people thinking on timing of next update - I feel we are already due.

[inanaco] 04/4/2024 08:02

just a reminder that some feel we won't get an update ....

since the last major update showing the graph with patients "responding" to one patient achieving "Complete response" as time on the trial continues by now other patients on the trial will also be responding ..

so what is to look forward to ?

More Complete response ? as well as a higher number responding .....

we know that approx the SCIB1 trial is recruited and iscib1 has started

the key is 33 responders

[marcusl2] 03/4/2024 14:48

If we can get CPIs approved for Modi-1 in Ovarian then hopefully those results improve further.

[marcusl2] 03/4/2024 14:46

Bermuda,

interesting to compare Modi-1 Ovarian data with Profound Bio


(Genmab buys ProfoundBio for $1.8 billion)


4) Their lead product has FDA Fast Track Designation and has produced some stunning early clinical results in ovarian/endometrial cancer patients with advanced metastatic inoperable disease who had failed on several previous lines of other therapies -

'Among 21 response-evaluable patients with ovarian and endometrial cancer, unselected for FRα expression, an initial objective response rate of 38% was observed (1 complete response (CR), 7 partial responses (PR)); an additional 9 patients had stable disease (SD), including 7 with decreasing tumor measurements'


Modi-1

ModiFY trial now recruiting patients for monotherapy and
for Modi-1 in combination with CPIs
44% of actively progressing ovarian cancer patients achieved stable disease
► Ovarian monotherapy cohort fully recruited (n=16)
► All patients failed on previous treatments and with actively progressing disease
► 44% (7/16) achieved stable disease for at least 8 weeks, with some patients experiencing stability for over 4 months
Dr David Pinato, Principal Investigator at Imperial College, commented:
“Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in
patients who have exhausted most treatment options is very encouraging”.
► Opportunity to improve response rate further in this difficult to treat ovarian cancer in combination therapy with
checkpoint inhibitors, not currently approved in this patient group
► Supporting data to be provided by other tumour types being studied in combination with checkpoint inhibitors
► Cohort 4 (n=3) fully recruited to assess safety of full dose Modi-1 in combination with nivolumab; safety review has now
allowed expansion cohorts (focussing on head & neck, renal cancers) and the neoadjuvant study
► Topline data expected to be reported during 2024

[ruckrover] 03/4/2024 11:46

marcus2,

Trinity Delta have a current value of 5.7p for the Immunobody platform.
This is based on a 7.5% chance of success and a launch year of 2029/2030.
If the data is good and they rate the chances of success as 12.5% (the same as they rate Moditope) then the value (according to TD) would rise to 9.2p - so nearly what it is trading at currently for the whole caboodle.

Something doesn't add up - hopefully it will soon!

[marcusl2] 03/4/2024 09:01

Surely the Immunobody platform should be worth this much on its own if phase 2 continues to look good.

[marcusl2] 03/4/2024 09:00

Genmab to acquire ProfoundBio for USD 1.8 billion in cash

[rogerbridge] 03/4/2024 07:28

It could be good timing for those share options.

[marcusl2] 02/4/2024 21:59

Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC